RxDoctor Payments DataLook up a doctor →

Bruce Ennis, MD

Interventional Cardiology · Mandeville, LANPI 1639134901

Payments from drug & device makers

$562,284in general payments, 2019–2025

Across 733 payments — averaging $767.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$362K
  • Amgen$74K
  • Bayer$49K
  • Sanofi US Services Inc.$32K
  • Medtronic$16K
  • Lexicon Pharmaceuticals, Inc.$10K
  • plus $21K from 40 others

What the payments were for

  • Speaking & faculty fees$6,60018%
  • Travel & lodging$10,49328%
  • Food & beverage$19,89354%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$562,284 in reported general payments places this provider in the 95th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$231,290
Medicare patients
1,118
Services billed
4,339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban321$239,027
EntrestoSacubitril/Valsartan144$123,581
Repatha SureclickEvolocumab107$67,643
XareltoRivaroxaban79$58,275
FarxigaDapagliflozin Propanediol48$33,346
BrilintaTicagrelor18$13,064
JardianceEmpagliflozin13$10,867
MultaqDronedarone Hcl11$8,430
Ranolazine ErRanolazine150$8,336
Metoprolol Succinate571$5,287
ClopidogrelClopidogrel Bisulfate407$2,971
Atorvastatin Calcium361$2,717
Propafenone Hcl ErPropafenone Hcl13$2,144
Losartan Potassium190$1,772
Isosorbide Mononitrate ErIsosorbide Mononitrate221$1,571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$724$239,027321 claims
NovartisEntresto$361,654$123,581144 claims
Johnson & JohnsonXarelto$192$58,27579 claims
AstraZenecaFarxiga, Brilinta$256$46,41066 claims
Boehringer IngelheimJardiance$137$10,86713 claims
Sanofi-aventis U.S. LLCMultaq$150$8,43011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Mandeville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →